TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Lake Street Capital

Lake Street Capital started coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI - Free Report) in a report issued on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $10.00 price objective on the stock.

A number of other equities analysts also recently commented on TLSI. Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They set an "outperform" rating and a $12.50 price objective for the company. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 price objective on the stock. Roth Mkm reaffirmed a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Canaccord Genuity Group dropped their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Finally, Roth Capital raised TriSalus Life Sciences to a "strong-buy" rating in a report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $11.56.

TriSalus Life Sciences Price Performance

Shares of NASDAQ TLSI traded up $0.12 during mid-day trading on Thursday, hitting $5.65. The company had a trading volume of 19,318 shares, compared to its average volume of 28,982. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42. The company has a market capitalization of $172.27 million, a PE ratio of -2.27 and a beta of 0.51. The business's 50-day simple moving average is $4.83 and its 200 day simple moving average is $4.73.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 4,826 shares of the firm's stock in a transaction dated Monday, January 27th. The stock was acquired at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the purchase, the chief executive officer now owns 429,503 shares of the company's stock, valued at approximately $2,327,906.26. This represents a 1.14 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Equity Ab Frankenius acquired 62,972 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the transaction, the insider now owns 6,230,748 shares in the company, valued at $24,736,069.56. The trade was a 1.02 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 124,868 shares of company stock worth $575,843. 32.80% of the stock is owned by insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Several institutional investors have recently made changes to their positions in TLSI. Bank of America Corp DE boosted its holdings in TriSalus Life Sciences by 120,471.6% during the fourth quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after buying an additional 178,298 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock worth $924,000 after acquiring an additional 62,542 shares in the last quarter. Bridgeway Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 333.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock worth $326,000 after acquiring an additional 50,000 shares in the last quarter. MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $184,000. Finally, Vestcor Inc purchased a new stake in TriSalus Life Sciences during the third quarter worth $108,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.